Abbott to close Exact Sciences acquisition on March 23, 2026

Reuters03-20 21:01
Abbott to close Exact Sciences acquisition on March 23, 2026
  • Abbott’s acquisition of Exact Sciences is expected to close on March 23, 2026, following receipt of all regulatory clearances necessary for closing.
  • The deal adds Exact Sciences’ cancer screening and diagnostics portfolio, including Cologuard and Oncotype DX, to Abbott’s diagnostics business.
  • The transaction is expected to add about USD 3.0 billion of incremental sales and dilute adjusted EPS by about USD 0.20.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abbott Laboratories published the original content used to generate this news brief via PR Newswire (Ref. ID: CG15115) on March 20, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment